Kaisernetwork.org (Washington, DC)
4 November 2008
Election 2008
Magazine Calls on Next President To Develop National HIV/AIDS Plan
[Nov 04, 2008]
Whichever candidate wins the U.S. presidential election should develop a national HIV/AIDS strategy, POZ magazine editor-in-chief Regan Hofmann said recently, VOA News reports. According to POZ, more than one million people in the U.S. are HIV-positive, and 14,000 people died from AIDS-related causes in 2006. In addition, about 25% of people in the U.S. who are living with HIV are unaware of their status, VOA News reports. According to Hofmann, the next president should "acknowledge" that there is an HIV/AIDS epidemic in the U.S. and put "forward a plan immediately to deal with it. The funding is not commensurate with the need in the United States." She added that several state and federal HIV/AIDS programs have seen budget cuts in recent years.
"For the entire epidemic to date, now almost 28 years, we've had sort of a combination of small grassroots work being done and then large-scale projects and initiatives, but there hasn't been the coordination that is needed to make sure that all of the people who are living with HIV can access care and treatment," Hofmann said, adding, "AIDS is not going away in America. It's a preventable disease. So, something's broken here because we know how to stop the disease. We can prevent the transmission of HIV and yet we're not. We know how to keep people alive and yet people are still dying of AIDS in America."
POZ put forth seven steps to address HIV/AIDS in the U.S., such as addressing stigma and discrimination, as well as identifying "evidence-based prevention tactics that work and tailor[ing] them to individual audiences." Hofmann also said that the blame and condemnation associated with HIV/AIDS should end. "This is a retrovirus," she said, adding, "It's nothing more and nothing less, but we have to change the way that people think about AIDS so that people aren't afraid to get tested. They aren't afraid to go and get care. People who have HIV didn't do anything bad. And yet society, and even those living with the disease, sometimes think otherwise."
According to Hofmann, many young people who were born after the initial fears surrounding HIV/AIDS are not aware of prevention measures and therefore are engaging in risky sexual behavior. She added that more funding should be devoted to developing a vaccine or cure for HIV/AIDS because of the rising costs of treatment and prevention. "This has become a global economic crisis," Hofmann said, adding, "It's been a humanitarian crisis for a long, long time. ... We're looking at how in the world the world is going to be able to pay for all of these people. So, there's absolutely incentive, I think, to look for the answer to this disease. We can't bear the cost of AIDS" (De Capua, VOA News, 11/3).
The related POZ article is available online.
Link to this story.
Science & Medicine
Study Examines Why Merck Vaccine Candidate Might Have Increased Likelihood of Contracting HIV
[Nov 04, 2008]
Trials of Merck's experimental HIV vaccine were halted in September 2007 because the drug might have increased the likelihood of contracting the virus rather than preventing it, according to a study published Monday in the Journal of Experimental Medicine, AFP/Google.com reports.
The vaccine was based on the idea that a modified form of a common cold virus -- Adenovirus 5 -- would carry elements of HIV into the body, which would then trigger the immune system to start fighting a subsequent HIV infection. An initial concern was that widespread immunity to the vaccine might cause it to be rejected by the body before the body could develop an effective response against HIV. However, three years after the trial began, researchers at the Montpellier Institute of Molecular Genetics in France said that more of the recipients who had prior immunity to the Ad5 virus had contracted HIV than those who had not received the vaccine. The study found that the presence of long-lasting antibodies specific to the Ad5 virus, which were generated during natural infections with the common cold, could have altered the response to the vaccine. Furthermore, HIV spread through cell cultures three times faster in the presence of antibodies from individuals immune to the Ad5 virus because HIV came in contact with an increased amount of CD4+ T cells to infect. In addition, the study found that the problem was not documented during Phase II trials because nonhuman primates, which were used in Phase I trials, do not naturally come into contact with the human common cold (AFP/Google.com, 11/3).
The study is available online.
Link to this story.
Global Challenges
First National Conference for People Living with HIV/AIDS Held in Papua New Guinea
[Nov 04, 2008]
Papua New Guinea's first national conference for people living with HIV was opened Sunday in the capital of Port Moresby by Jamie Maxtone-Graham, chair of the Special Parliamentary Committee on HIV/AIDS, the Papua New Guinea Post-Courier reports. The three-day event -- which is funded by the Australian government through Sanap Wantaim, Australia's HIV/AIDS program with Papua New Guinea -- is expected to draw about 150 people living with HIV. According to the Post-Courier, about 60% of HIV-positive people in the country have not publically disclosed their HIV status. Participants include 47 representatives from Papua New Guinea's 20 provinces, as well as international representatives from the National Association of People with AIDS in Australia, the Aboriginal and Torres Strait Islands, the Solomon Islands and the Pacific Islands Association Federation in the Cook Islands.
Annie MacPherson, coordinator for Igat Hope, said the event marks the first time people who are living with HIV/AIDS in Papua New Guinea are being brought together to "develop a way forward on how they can work with each other in the national HIV response." The focus of the conference will be discussions on universal access to treatment, leadership and support for people living with HIV. According to the Post-Courier, more than 1,000 people living with HIV/AIDS in the country have access to antiretroviral treatment.
Anne Malcom, team leader for Sanap Wantaim, said that Australia recognizes the HIV epidemic in Papua New Guinea and is committed to helping the country increase its long-term response to the virus. Community Development Minister Dame Carol Kidu said the conference is possible because of the few people living with HIV in Papua New Guinea who publically reveal their status. She added that years ago, there was an even greater fear surrounding HIV in the country. Kidu also urged advocates to include issues such as tuberculosis drug access in their efforts to increase HIV/AIDS drug access in the country (Gerawa, Papua New Guinea Post-Courier, 11/3).
Link to this story.
Glaser Foundation Program Trains HIV-Positive Pregnant Women To Administer Nevirapine to Infants Following Home Births
[Nov 04, 2008]
The Elizabeth Glaser Pediatric AIDS Foundation has completed the pilot phase of a home-based program in Uganda that teaches HIV-positive pregnant women how to administer the antiretroviral nevirapine to their infants immediately after birth to prevent mother-to-child transmission of the virus, New Vision reports. According to New Vision, the pediatric form of nevirapine can reduce an infant's risk of HIV by 50% when given after birth.
Under the program, nevirapine is repackaged to allow pregnant women who do not give birth at a heath facility to administer the formula at home. The package consists of a sealed syringe of the medication wrapped in foil paper that prevents sun exposure and includes instructions in local languages. It will be integrated into existing prenatal programs, New Vision reports.
According to Edward Bitarakwate, the foundation's technical director, a "big challenge" for the program will be to ensure the medication is not given to women early in their pregnancies because it could expire before the women give birth. The foundation is "discussing training [and] dispensing technicalities with the Ministry of Health," Bitarakwate said. "It is pointless to give [nevirapine] to the mother in early pregnancy as it may expire before the baby comes," Bitarakwate added.
Be the first to Write a Comment!
AllAfrica aggregates and indexes content from over 125 African news organizations, plus more than 200 other sources, who are responsible for their own reporting and views. Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica.
